The estimated Net Worth of Kary Eldred is at least $274 Thousand dollars as of 22 July 2024. Mr. Eldred owns over 400 units of Galectin Therapeutics Inc stock worth over $136,214 and over the last 6 years he sold GALT stock worth over $0. In addition, he makes $138,284 as Independent Director at Galectin Therapeutics Inc.
Sign up
Mr. Eldred GALT stock SEC Form 4 insiders trading
Kary has made over 7 trades of the Galectin Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 400 units of GALT stock worth $956 on 22 July 2024.
The largest trade he's ever made was buying 3,033 units of Galectin Therapeutics Inc stock on 31 May 2019 worth over $12,981. On average, Kary trades about 702 units every 152 days since 2018. As of 22 July 2024 he still owns at least 49,713 units of Galectin Therapeutics Inc stock.
You can see the complete history of Mr. Eldred stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kary Eldred biography
Kary N. Eldred serves as Independent Director of the Company. In these capacities, he serves and has served on a number of corporate boards of companies with potential for and driving toward initial public offerings and is currently serving as a board member in Buy It Installed (since 2017), Babywise and Wise King Media (since 2015). Kary Eldred also served on the board and audit committee of GCT Semiconductor. From January 2011 through October 2014, Mr. Eldred was CEO & Chairman of Altadona, S.A. a software integration company based in Europe and prior to that was a principal in Parakletos Ventures, an institutional venture capital firm with several investments in companies that went on to be acquired or become publicly listed on different exchanges around the world including the NASDAQ, KOSDAQ and the GEM market. Mr. Eldred has an Executive MBA from IE Business School and a BA in Foreign Service from Baylor University.
What is the salary of Kary Eldred?
As the Independent Director of Galectin Therapeutics Inc, the total compensation of Kary Eldred at Galectin Therapeutics Inc is $138,284. There are 10 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.
How old is Kary Eldred?
Kary Eldred is 46, he's been the Independent Director of Galectin Therapeutics Inc since 2018. There are 19 older and no younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.
What's Kary Eldred's mailing address?
Kary's mailing address filed with the SEC is 4960 Peachtree Industrial Blvd #240, Norcross, GA 30071, USA.
Insiders trading at Galectin Therapeutics Inc
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr, and Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
What does Galectin Therapeutics Inc do?
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
What does Galectin Therapeutics Inc's logo look like?
Complete history of Mr. Eldred stock trades at Galectin Therapeutics Inc
Galectin Therapeutics Inc executives and stock owners
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Harold Shlevin,
Director -
Jack Callicutt,
Chief Financial Officer, Secretary -
Dr. Pol F. Boudes M.D., Ph.D.,
Chief Medical Officer -
Dr. Pol F. Boudes,
Chief Medical Officer -
Joel Lewis,
Pres, CEO & Director -
Kevin Freeman,
Independent Director -
Joel Lewis,
President, Chief Executive Officer, Director -
Richard Uihlein,
Independent Chairman of the Board -
Gilbert Amelio,
Independent Director -
Gilbert Omenn,
Independent Director -
Kary Eldred,
Independent Director -
Eliezer Zomer,
Executive Vice President - Manufacturing and Product Development -
Marc Rubin,
Independent Director -
James Czirr,
Director -
Richard Zordani,
Independent Director -
Elissa Schwartz,
Independent Director -
Pol Boudes,
Chief Medical Officer -
J. Rex Horton,
Executive Director - Regulatory Affairs and Quality Assurance -
Adam Allgood,
Executive Director of Clinical Development -
Beth Knowles,
Exec. Assistant & Officer Mang. -
Robert Tritt,
Gen. Counsel -
Jack W. Callicutt CPA, CPA,
CFO, Treasurer & Sec. -
Theodore Daniel Zucconi,
Director -
John F Mauldin,
Director -
Fund, L.P.10 X Capital Mana...,
-
Steven Prelack,
Director -
Arthur Greenberg,
Director -
Khurram Jamil,
Chief Medical Officer -
Benjamin Sr Carson,
-
Stephen Shulman,
Director -
Fund, L.P.10 X Capital Mana...,
-
Peter G Traber,
CEO and President -
Herman Paul Pressler,
Director -
Thomas Mcgauley,
Chief Financial Officer -
Rod D Martin,
Director -
Jerald K Rome,
Director -
Fund, L.P.Czirr James C10 X...,